Table 1:
Limited clinical characteristics of concurrent PTEN and DICER1 mutant endometrial cancers
| NCI -UCC n = 16 |
MSK -PATH n = 30 |
MSK -IMPACT n = 189 |
TCGA PanCancer n = 509 |
||
|---|---|---|---|---|---|
| Both mutations, n (%) | 0 | 3 (10%) | 5 (2.6%) | 57 (11.2%) | |
| Cancer histology, n (%) | Endometrioid | -- | -- | 4 (80%) | 54 (94.7%) |
| Uterine Carcinosarcoma | -- | -- | 1 (20%) | -- | |
| Clear cell | -- | 3 (100%) | -- | -- | |
| Mixed serous and endometrioid | -- | -- | 2 (3.5%) | ||
| Serous | -- | -- | 1 (1.8%) | ||
| Histologic grade, n (%) | Grade 1 | -- | -- | 1 (20%) | 7 (12.3%) |
| Grade 2 | -- | 3 (100%) | -- | 9 (15.8%) | |
| Grade 3 | -- | -- | 4 (80%) | 41 (71.9%) | |
| Molecular category, n (%) | MSS | -- | -- | 1 (20%) | -- |
| MSI-H | -- | -- | 2 (40%) | 17 (29.8%) | |
| POLE ultra-mutated | -- | 2 (66.7%) | 2 (40%) | 34 (59.7%) | |
| Copy-number low | -- | -- | -- | 6 (10.5%) | |
| Disease progression, n (%) | No disease progression | -- | 3 (100%) | 1 (20%) | 5 (8.8%) |
| Disease progression | -- | -- | 4 (80%) | 52 (91.2%) |